Targeting FoxO transcription factors with HDAC inhibitors for the treatment of osteoarthritis.

Hiroki OhzonoYiwen HuKeita NagiraHaruhisa KanayaNaoki OkuboMerissa OlmerMasafumi GotohIchiro KurakazuYukio AkasakiManabu KawataEmily ChenAlan C ChuKristen A JohnsonMartin K Lotz

Published in: Annals of the rheumatic diseases (2022)

Panobinostat has a clinically relevant activity profile and is a candidate for OA symptom and structure modification.

Keyphrases

transcription factor
histone deacetylase
knee osteoarthritis
signaling pathway
cancer therapy